Co-Diagnostics logo

Co-DiagnosticsNASDAQ: CODX

Profile

Sector:

Healthcare

Country:

United States

IPO:

12 July 2017

Next earnings report:

14 March 2025

Last dividends:

N/A

Next dividends:

N/A
$33.21 M
-89%vs. 3y high
30%vs. sector
-vs. 3y high
-vs. sector
-82%vs. 3y high
27%vs. sector
-54%vs. 3y high
60%vs. sector

Price

after hours | Wed, 20 Nov 2024 23:02:15 GMT
$1.04-$0.02(-1.89%)

Dividend

No data over the past 3 years
$641.10 K$375.00 K
$641.10 K-$9.70 M

Analysts recommendations

Institutional Ownership

CODX Latest News

Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024
prnewswire.com05 November 2024 Sentiment: POSITIVE

SALT LAKE CITY , Nov. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth and delivering a presentation at the MEDICA 2024 trade fair in Düsseldorf, Germany on November 11-14. MEDICA has become the largest medical B2B trade fair in the world, attracting 83,000 visitors and over 5,300 exhibitors from almost 70 countries.

Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast
prnewswire.com25 October 2024 Sentiment: POSITIVE

SALT LAKE CITY , Oct. 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2024 results on Thursday, November 7, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3
prnewswire.com02 October 2024 Sentiment: POSITIVE

SALT LAKE CITY , Oct. 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at the Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) Convention & Expo at the Mountain America Expo Center in Sandy, Utah on October 2-3, 2024. The UHCA/UCAL Convention includes sessions and events for executive leadership, administrators, corporate personnel, owners, and Directors of Nursing for skilled nursing, assisted living and intermediate care facilities, and will include an expo for companies to exhibit their products and services relevant to these industries.

Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: NEUTRAL

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Jade Montgomery - H.C. Wainwright Operator Good day, and welcome to the Co-Diagnostics Second Quarter 2024 Earnings Conference Call.

Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates
zacks.com08 August 2024 Sentiment: POSITIVE

Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.

Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago
prnewswire.com29 July 2024 Sentiment: POSITIVE

SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is hosting a booth at the Association for Diagnostics & Laboratory Medicine (ADLM) annual meeting and expo held July 28-August 1, 2024, in Chicago, IL. Co-Dx will also be holding a special company presentation to discuss the role of its new at-home and point-of-care Co-Dx™ PCR platform* in closing the global diagnostics gap for an array of potential indications, including tuberculosis (TB).

Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast
prnewswire.com25 July 2024 Sentiment: POSITIVE

SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2024 results on Thursday, August 8, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

Co-Diagnostics, Inc. to Participate at FIME 2024 in Miami Beach, June 19-21
prnewswire.com18 June 2024 Sentiment: POSITIVE

SALT LAKE CITY , June 18, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has been invited to participate in the Utah booth at the FIME trade show in Miami Beach, Florida, on June 19-21. FIME is described as the Americas' leading medical trade expo for medical device and product purchasers, for establishing new supplier relationships, and for strengthening business ties with the global medical device and equipment market, with exhibitors from 116 countries and more than 15,000 expected professional attendees.

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform
prnewswire.com14 June 2024 Sentiment: POSITIVE

The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other tests in the pipeline to meet the needs of a global market SALT LAKE CITY , June 14, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has completed its first U.S. Food and Drug Administration (FDA) application for 510(k) clearance for the Co-Dx™ PCR Pro™ instrument, and the Co-Dx PCR COVID-19 Test for over-the-counter (OTC) use. Co-Diagnostics completed the submission via the FDA's electronic Submissions Template And Resource (eSTAR) system, and have received the acknowledgement from the FDA that the 510(k) application was received.

Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast
PRNewsWire25 April 2024 Sentiment: POSITIVE

Co-Diagnostics, Inc., a molecular diagnostics company with a patented platform for developing molecular diagnostic tests, will release its first quarter 2024 financial results on May 9, 2024, after the market closes. The Company will also hold a conference call and webcast at 4:30 p.m. on the same day.

What type of business is Co-Diagnostics?

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

What sector is Co-Diagnostics in?

Co-Diagnostics is in the Healthcare sector

What industry is Co-Diagnostics in?

Co-Diagnostics is in the Medical Devices industry

What country is Co-Diagnostics from?

Co-Diagnostics is headquartered in United States

When did Co-Diagnostics go public?

Co-Diagnostics initial public offering (IPO) was on 12 July 2017

What is Co-Diagnostics website?

https://www.codiagnostics.com

Is Co-Diagnostics in the S&P 500?

No, Co-Diagnostics is not included in the S&P 500 index

Is Co-Diagnostics in the NASDAQ 100?

No, Co-Diagnostics is not included in the NASDAQ 100 index

Is Co-Diagnostics in the Dow Jones?

No, Co-Diagnostics is not included in the Dow Jones index

When was Co-Diagnostics the previous earnings report?

No data

When does Co-Diagnostics earnings report?

The next expected earnings date for Co-Diagnostics is 14 March 2025